IsoRay announces first human prostate implant using Cesium-131 isotope seeds IsoRay announced the first prostate cancer implant combining IsoRay's Cesium-131 seeds with C4 Imaging's Sirius positive signal MRI markers. IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen to partner with C4 Imaging's innovative positive signal MRI markers in the treatment of prostate cancer. By combining two of the newest technologies available in brachytherapy, we hope to demonstrate superior outcomes with the goal of improving patient lives. As we continue to develop our product offerings both internally and in partnership with other industry leaders, our message is clear and the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients."
News For ISR From The Last 14 Days
Check below for free stories on ISR the last two weeks.